Ranbaxy Drugs at Fourth Plant Banned From U.S. Market
This article is for subscribers only.
Ranbaxy Laboratories Ltd., the drugmaker controlled by Japan’s Daiichi Sankyo Co., can’t make or distribute drug ingredients from a fourth plant in India for the U.S. market, regulators ordered. The stock plunged.
A U.S. Food and Drug Administration inspection of Ranbaxy’s Toansa facility found that workers retested drug products to produce acceptable findings after the items originally failed analytical testing. Ranbaxy fell as much as 20 percent in Mumbai trading, while parent Daiichi Sankyo declined as much as 6.9 percent in Tokyo.